Rauf Baba, MD
Endocrinology, Diabetes & Metabolism · Dyersburg, TNNPI 1689677296
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,672 of the $25,780 with a category attached, or 80.2%. It is spread thinly across 45 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $7,966 and has fallen 54.8% since, to $3,599 in 2025.
Across 1,225 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Lilly USA, LLC$3K
- Novo Nordisk$3K
- Boehringer Ingelheim$3K
- AstraZeneca$2K
- Abbott$949
- plus $10K from 39 others
What the payments were for
- Speaking & faculty fees$4,89019%
- Travel & lodging$1501%
- Food & beverage$20,67280%
- Education$80%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,780 in reported general payments places this provider in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,057 | $1,093,005 |
| JardianceEmpagliflozin | 882 | $684,906 |
| MounjaroTirzepatide | 531 | $593,856 |
| TrulicityDulaglutide | 252 | $297,529 |
| FarxigaDapagliflozin Propanediol | 268 | $228,834 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 184 | $209,048 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 151 | $122,258 |
| Tresiba Flextouch U-200Insulin Degludec | 176 | $119,066 |
| Tresiba Flextouch U-100Insulin Degludec | 141 | $104,869 |
| JanumetSitagliptin Phos/Metformin Hcl | 139 | $104,673 |
| KerendiaFinerenone | 103 | $93,861 |
| ForteoTeriparatide | 20 | $91,217 |
| JanuviaSitagliptin Phosphate | 109 | $87,568 |
| Novolog FlexpenInsulin Aspart | 314 | $78,325 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $75,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp, Rybelsus | $2,855 | $1,240,3761,414 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $3,402 | $1,046,8041,052 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Glyxambi | $2,836 | $783,3851,007 claims |
| MerckJanumet Xr, Janumet, Januvia | $4,130 | $314,499399 claims |
| AstraZenecaFarxiga | $1,653 | $228,834268 claims |
| BayerKerendia | $574 | $93,861103 claims |
| AbbVieSynthroid | $940 | $33,967483 claims |
| Mannkind CorporationAfrezza | $813 | $22,01525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Dyersburg
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- David EscalanteJellico$326K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.